[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651031":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":37,"collaborators":41,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Taichung Veterans General Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Lung Cancer Group",null,"Adult participants with pathologically confirmed lung cancer, including adenocarcinoma, squamous cell carcinoma, or small cell lung cancer. Participants will provide peripheral blood samples annually for three years for Raman biochip testing and biomarker analysis.",{"label":13,"type":10,"description":14,"interventionNames":10},"Non-Lung Cancer Group","Adult participants without a diagnosis of lung cancer who underwent low-dose computed tomography or chest computed tomography within the previous two years and who have no pulmonary nodule or ground-glass lesion, or a lesion smaller than 0.4 cm. Participants may have chronic pulmonary diseases such as chronic obstructive pulmonary disease, asthma, bronchiectasis, or pulmonary fibrosis. One peripheral blood sample will be collected at enrollment.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"CRC, MSC","CONTACT","886 4-23592525 #6535","yetquen@gmail.com",[22],{"facility":5,"status":23,"city":24,"state":10,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"RECRUITING","Taichung","407219","Taiwan","TW",{"type":29,"coordinates":30},"Point",[31,32],120.6839,24.1469,{"lat":32,"lon":31},[35],{"name":36,"role":18,"phone":10,"phoneExt":10,"email":10},"Pin-Kuei",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Pin-Kuei Fu, MD, PhD","Director, Division of Clinical Trials, Department of Medical Research",[42,44],{"name":43,"class":6},"Far Eastern Memorial Hospital",{"name":45,"class":46},"Taoyuan General Hospital, Ministry of Health and Welfare","OTHER_GOV","100651031","nitride-based-raman-biochip-for-lung-cancer-diagnosis-and-monitoring-100651031",false,"NCT07755020","Nitride-Based Raman Biochip for Lung Cancer Diagnosis and Monitoring","Utilizing a Nitride-Based Raman Biochip for Assisting in Lung Cancer Diagnosis and Clinical Monitoring: A Prospective, Multicenter Clinical Study","Inclusion Criteria:\n\n* Lung Cancer Group:\n\n  1. Age 18 years or older.\n  2. Underwent low-dose computed tomography or chest computed tomography within the previous 2 years.\n  3. Pathologically confirmed lung cancer.\n  4. Histological diagnosis of adenocarcinoma, squamous cell carcinoma, or small cell lung cancer, with TNM stage determined by a thoracic physician.\n  5. Willing to provide approximately 20 mL of peripheral blood annually for 3 years.\n  6. Able to understand the study information and provide written informed consent.\n  7. Agrees to linkage of study data with relevant health insurance and mortality databases, as applicable.\n\nNon-Lung Cancer Group:\n\n1. Age 18 years or older.\n2. Underwent low-dose computed tomography or chest computed tomography within the previous 2 years.\n3. No pulmonary nodule or ground-glass lesion, or a pulmonary nodule or ground-glass lesion smaller than 0.4 cm.\n4. May have a chronic pulmonary disease, including chronic obstructive pulmonary disease, asthma, bronchiectasis, or pulmonary fibrosis.\n5. Willing to provide one peripheral blood sample of approximately 20 mL.\n6. Able to understand the study information and provide written informed consent.\n7. Agrees to linkage of study data with relevant health insurance and mortality databases, as applicable.\n\nExclusion Criteria:\n\n* 1\\. Younger than 18 years of age. 2. Unable to understand the study information or provide written informed consent.\n\n  3\\. For the non-lung cancer group, presence of a pulmonary nodule or ground-glass lesion greater than 0.4 cm.\n\n  4\\. Unwilling to provide a peripheral blood sample. 5. Unwilling to permit linkage with the National Health Insurance research data system.","ALL","18 Years",{"count":57,"type":58},3000,"ESTIMATED","OBSERVATIONAL","This prospective, multicenter observational study aims to evaluate the diagnostic and clinical monitoring performance of a nitride-based Raman biochip in participants with and without lung cancer. Peripheral blood samples will be collected and analyzed using the Raman biochip to characterize molecular spectral patterns and assess their association with the current standard diagnosis of lung cancer.\n\nThe study plans to enroll 2,000 participants with pathologically confirmed lung cancer and 1,000 participants without lung cancer. Diagnostic performance will be evaluated using measures including sensitivity, specificity, positive predictive value, negative predictive value, and receiver operating characteristic curve analysis. Exploratory analyses will assess performance according to lung cancer histological subtype, disease stage, and longitudinal clinical status.",[62,63],"Lung Cancer (Diagnosis)","Lung Neoplasms",[65,66,67,68,69,70,71,72,73],"Nitride-based Raman biochip","Raman spectroscopy","Surface-enhanced Raman scattering","Lung cancer diagnosis","Blood biomarker","Molecular fingerprint","Clinical monitoring","Artificial intelligence","Diagnostic accuracy","2026-08-05",{"date":76,"type":77},"2026-08-10","ACTUAL",{"date":79,"type":77},"2025-08-04",{"date":81,"type":58},"2032-12-31",{"name":5,"class":6},1]